Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | YWHAG | P61981 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 6/20 | 0.32 |
| ▸ | MAOA | P21397 | 4/20 | 0.32 |
| ▸ | MAOB | P27338 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31716197 | 0.76 | CUL4A (0.35) | ALDH1A1HPGDKDM1AMAOAMAOB | |
| SCHEMBL3992251 | 0.76 | KDM1A (0.36) | ALDH1A1KDM1AMAOAMAOB | |
| SCHEMBL16428784 | 0.76 | ALDH1A1 (0.33) | ALDH1A1HPGDKDM4EMEN1HSP90AA1 | |
| SCHEMBL20520159 | 0.76 | KDM1A (0.33) | ALDH1A1HPGDKDM4EMEN1MAPT | |
| SCHEMBL1153469 | 0.74 | KDM1A (0.44) | KDM1AMAOAMAOB | |
| SCHEMBL20017698 | 0.73 | HTR2A (0.35) | KDM1AMAOAMAOB | |
| SCHEMBL13818654 | 0.73 | KDM1A (0.34) | KDM1AMAOAMAOB | |
| SCHEMBL11266183 | 0.73 | KDM1A (0.34) | KDM1AMAOAMAOB | |
| SCHEMBL8070798 | 0.72 | KDM1A (0.33) | KDM1A | |
| SCHEMBL9842972 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118510512-A | Novel process for the preparation of 4'- (bromomethyl) [1,1' -biphenyl ] -2-carbonitrile | 阿尔第实业有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023157026-A1 | A NOVEL PROCESS FOR THE PREPARATION OF 4'-(BROMOMETHYL)[1,1'-BIPHENYL]-2-CARBONITRILE | AARTI INDUSTRIES LIMITED (IN) | 2023-08-24 | — | — | WO | disclosed |
| CN-108732279-B | Method for analyzing and determining genotoxic impurities in valsartan by using HPLC (high performance liquid chromatography) method | 齐鲁制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114436833-A | Preparation method of telmisartan key intermediate 4' -methylbiphenyl-2-carboxylic ester | 南京红太阳医药研究院有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-110183354-A | A method of 4 '-bromomethyl -2- cyanobiphenyls are prepared using the continuous bromination reaction of illumination | 山东汉兴医药科技有限公司 | 2019-08-30 | — | — | CN | disclosed |
| CN-102070465-B | Method for preparing phenylaniline | CHANGCHUN APPLIED CHEMISTRY | 2013-12-18 | — | — | CN | disclosed |
| US-20120225896-A1 | NOVEL 2-PYRIDONE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | KOWA COMPANY, LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| CN-102070465-A | Method for preparing phenylaniline | CHANGCHUN APPLIED CHEMISTRY | 2011-05-25 | — | — | CN | disclosed |
| CN-1285570-C | Process for producing 4'-bromomethyl-2-cyanobiphenyl | SUMITOMO CHEMICAL CO (JP) | 2006-11-22 | — | — | CN | disclosed |
| CN-1810774-A | A process for producing an aralkyl compound, a dehalogenation method of an aralkyl halide compound and a method for recovering an aralkyl compound | SUMITOMO CHEMICAL CO (JP) | 2006-08-02 | — | — | CN | disclosed |
| CN-1628094-A | Method for producing 4' -bromomethyl-2-cyanobiphenyl | SUMIKA FINE CHEMICALS CO LTD (JP) | 2005-06-15 | — | — | CN | disclosed |
| EP-0253310-A2 | Angiotensin II receptor blocking imidazoles | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225896-A1 | NOVEL 2-PYRIDONE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | PPARG, PPARD, PPARA | ALDH1A1 563/4885HPGD 190/4885KDM4E 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.